Literature DB >> 19888961

Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators?

Pan Wang1, Yujing Wen, Gui-Zhen Han, Pritam Kaur Sidhu, Bao Ting Zhu.   

Abstract

BACKGROUND AND
PURPOSE: The endogenous oestrogens have important biological functions in men as well as in women. Because 17beta-oestradiol and oestrone are also formed in the male body, these aromatic oestrogens are generally thought to be responsible for exerting the required oestrogenic functions in the male. In the present study, we tested the hypothesis that some of the non-aromatic steroids that are androgen precursors or metabolites with hydroxyl groups at C-3 and/or C-17 positions may also be able to serve as ligands for the oestrogen receptors (ER) in the male. EXPERIMENTAL APPROACH: A total of sixty non-aromatic steroids (selected from families of androstens, androstans, androstadiens, oestrens and oestrans) were analysed for their ability to bind and activate the human ERalpha and ERbetain vitro and in cultured cells. KEY
RESULTS: Six of the non-aromatic steroids, that is, 5-androsten-3beta,17beta-diol, 5alpha-androstan-3beta,17beta-diol, 5(10)-oestren-3alpha,17beta-diol, 5(10)-oestren-3beta,17beta-diol, 4-oestren-3beta,17beta-diol and 5alpha-oestran-3beta,17beta-diol, were found to have physiologically relevant high binding affinity ( approximately 50% of that of oestrone) for human ERalpha and ERbeta. These non-aromatic steroids also activated the transcriptional activity of human ERs and elicited biological responses (such as growth stimulation) in two representative ER-positive human cancer cell lines (MCF-7 and LNCaP) with physiologically relevant potency and efficacy. Molecular docking analysis of these six active compounds showed that they could bind to ERalpha and ERbeta in a manner similar to that of 17beta-oestradiol. CONCLUSIONS AND IMPLICATIONS: These results provide evidence for the possibility that some of the endogenous androgen precursors or metabolites could serve as male-specific ER ligands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888961      PMCID: PMC2801221          DOI: 10.1111/j.1476-5381.2009.00467.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

Review 1.  17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes.

Authors:  H Peltoketo; V Luu-The; J Simard; J Adamski
Journal:  J Mol Endocrinol       Date:  1999-08       Impact factor: 5.098

Review 2.  The importance of oestrogens in males.

Authors:  Willem de Ronde; Huibert A P Pols; Johannes P T M van Leeuwen; Frank H de Jong
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

3.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

Review 4.  Functional role of estrogen metabolism in target cells: review and perspectives.

Authors:  B T Zhu; A H Conney
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

5.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth.

Authors:  Zhang Weihua; Richard Lathe; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

Review 6.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.

Authors:  Jacques Simard; Marie-Louise Ricketts; Sébastien Gingras; Penny Soucy; F Alex Feltus; Michael H Melner
Journal:  Endocr Rev       Date:  2005-01-04       Impact factor: 19.871

7.  Formation of 19-norsteroids by in situ demethylation of endogenous steroids in stored urine samples.

Authors:  J Grosse; P Anielski; P Hemmersbach; H Lund; R K Mueller; C Rautenberg; D Thieme
Journal:  Steroids       Date:  2005-03-29       Impact factor: 2.668

8.  Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.

Authors:  Zhi-Jian Liu; Bao Ting Zhu
Journal:  J Steroid Biochem Mol Biol       Date:  2004-03       Impact factor: 4.292

9.  Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice.

Authors:  J Lindzey; W C Wetsel; J F Couse; T Stoker; R Cooper; K S Korach
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

10.  Structure-based design of estrogen receptor-beta selective ligands.

Authors:  Eric S Manas; Rayomand J Unwalla; Zhang B Xu; Michael S Malamas; Chris P Miller; Heather A Harris; Chulai Hsiao; Tatos Akopian; Wah-Tung Hum; Karl Malakian; Scott Wolfrom; Ashok Bapat; Ramesh A Bhat; Mark L Stahl; William S Somers; Juan C Alvarez
Journal:  J Am Chem Soc       Date:  2004-11-24       Impact factor: 15.419

View more
  5 in total

1.  Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.

Authors:  Xiang-Rong Jiang; Pan Wang; Carolyn L Smith; Bao Ting Zhu
Journal:  J Med Chem       Date:  2013-03-26       Impact factor: 7.446

2.  Comparative molecular field analysis and molecular dynamics studies of the dopamine D2 receptor antagonists without a protonatable nitrogen atom.

Authors:  Agnieszka A Kaczor; Justyna Żuk; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2018-02-13       Impact factor: 1.965

3.  Testosterone protects female embryonic heart H9c2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B.

Authors:  Thomas Ballantyne; Qingyou Du; Sofija Jovanović; Andrew Neemo; Robert Holmes; Sharabh Sinha; Aleksandar Jovanović
Journal:  Int J Biochem Cell Biol       Date:  2012-10-22       Impact factor: 5.085

4.  Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations.

Authors:  Toru Hanamura; Tokiko Ito; Toshiharu Kanai; Kazuma Maeno; Yasuyo Shimojo; Takeshi Uehara; Takashi Suzuki; Shin-Ichi Hayashi; Ken-Ichi Ito
Journal:  Cancer Med       Date:  2016-05-03       Impact factor: 4.452

5.  Activation of Neuregulin 1/ErbB Signaling Is Involved in the Development of TOCP-Induced Delayed Neuropathy.

Authors:  Hai-Yang Xu; Pan Wang; Ying-Jian Sun; Ming-Yuan Xu; Li Zhu; Yi-Jun Wu
Journal:  Front Mol Neurosci       Date:  2018-04-23       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.